Skip to main content
SpringerLink
Log in

Regional Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma

  • Chapter
  • First Online:
Primary and Metastatic Liver Tumors

Abstract

Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have a poor prognosis and have historically benefited from very few treatment options. In the last 10 years, image-guided locoregional therapies have been developed to administer targeted treatment to the liver and are increasingly used in primary hepatic malignancies such as ICC. Locoregional therapies primarily consist of ablation and intra-arterial therapies, including conventional transarterial chemoembolization (cTACE), TACE with drug-eluting beads (DEB-TACE), and yttrium-90 radioembolization (Y90-RE). Current clinical evidence suggests that these treatments result in prolonged survival without significantly diminishing patient’s quality of life. This chapter aims to describe each locoregional therapy and the clinical evidence supporting its therapeutic application to unresectable ICC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Buettner S, van Vugt JL, JN IJ, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131–42.

    Article  CAS  Google Scholar 

  2. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.

    Article  Google Scholar 

  3. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806–13.

    Article  Google Scholar 

  4. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):101–4.

    Article  Google Scholar 

  5. Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90(4):817–37.

    Article  Google Scholar 

  6. Kim Y, Moris DP, Zhang XF, Bagante F, Spolverato G, Schmidt C, et al. Evaluation of the 8th edition American joint commission on cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol. 2017;116(6):643–50.

    Article  Google Scholar 

  7. Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189–200.

    Article  CAS  Google Scholar 

  8. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.

    Article  Google Scholar 

  9. Valls C, Guma A, Puig I, Sanchez A, Andia E, Serrano T, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25(5):490–6.

    Article  CAS  Google Scholar 

  10. Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol. 1998;171(3):651–8.

    Article  CAS  Google Scholar 

  11. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9(1):43–57.

    Article  Google Scholar 

  12. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–74.

    Article  Google Scholar 

  13. Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6(1):7–21.

    Article  Google Scholar 

  14. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736–50 e4.

    Article  Google Scholar 

  15. Lee JI, Campbell JS. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol. 2014;61(2):432–4.

    Article  Google Scholar 

  16. Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):79–90.

    Article  Google Scholar 

  17. Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22–34.

    Article  Google Scholar 

  18. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol. 2008;15(2):600–8.

    Article  Google Scholar 

  19. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79.

    Article  Google Scholar 

  20. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.

    Article  CAS  Google Scholar 

  21. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  Google Scholar 

  22. Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811–8.

    Article  Google Scholar 

  23. Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86.

    Article  Google Scholar 

  24. Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26(2):81–96.

    CAS  PubMed  Google Scholar 

  25. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 2008;14(2):117–22.

    Article  Google Scholar 

  26. Minami Y, Kudo M. Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI. Liver Cancer. 2015;4(2):106–14.

    Article  CAS  Google Scholar 

  27. Cohen MJ, Levy I, Barak O, Bloom AI, Fernandez-Ruiz M, Di Maio M, et al. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014;34(7):1109–17.

    Article  Google Scholar 

  28. Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012;131(3):733–40.

    Article  CAS  Google Scholar 

  29. Pomoni M, Malagari K, Moschouris H, Spyridopoulos TN, Dourakis S, Kornezos J, et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepato-Gastroenterology. 2012;59(115):820–5.

    CAS  PubMed  Google Scholar 

  30. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16(3):353–61.

    Article  Google Scholar 

  31. Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35(9):2083–91.

    Article  CAS  Google Scholar 

  32. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498–505.

    Article  CAS  Google Scholar 

  33. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2008;12(1):129–37.

    Article  Google Scholar 

  34. Scheuermann U, Kaths JM, Heise M, Pitton MB, Weinmann A, Hoppe-Lotichius M, et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience. Eur J Surg Oncol. 2013;39(6):593–600.

    Article  CAS  Google Scholar 

  35. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12(8):2563–7.

    Article  CAS  Google Scholar 

  36. Lewis AL, Dreher MR, O'Byrne V, Grey D, Caine M, Dunn A, et al. DC BeadM1: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med. 2016;27(1):13.

    Article  Google Scholar 

  37. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31(5):883–8.

    Article  Google Scholar 

  38. Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. 2014;37(1):154–64.

    Article  Google Scholar 

  39. Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2009;32(6):1187–92.

    Article  Google Scholar 

  40. Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–8.

    Article  Google Scholar 

  41. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.

    CAS  PubMed  Google Scholar 

  42. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.

    Article  Google Scholar 

  43. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.

    Article  Google Scholar 

  44. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–8.

    Article  Google Scholar 

  45. Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–16.

    Article  Google Scholar 

  46. Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.

    Article  Google Scholar 

  47. Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc. 2009;70(3):561–7.

    Article  Google Scholar 

  48. Rodriguez-Lago I, Carretero C, Herraiz M, Subtil JC, Betes M, Rodriguez-Fraile M, et al. Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. World J Gastroenterol. 2013;19(19):2935–40.

    Article  Google Scholar 

  49. Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestino F, Renzulli M, et al. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncol. 2017;13(15):1301–10.

    Article  CAS  Google Scholar 

  50. Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198.

    Article  Google Scholar 

  51. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.

    Article  CAS  Google Scholar 

  52. Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.

    Article  Google Scholar 

  53. Hickey R, Mulcahy MF, Lewandowski RJ, Gates VL, Vouche M, Habib A, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88(5):1025–31.

    Article  Google Scholar 

  54. Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol. 2012;85(1016):1078–84.

    Article  Google Scholar 

  55. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):2–6.

    Article  Google Scholar 

  56. Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg. 2002;68(4):395–7.

    PubMed  Google Scholar 

  57. Simo KA, Halpin LE, McBrier NM, Hessey JA, Baker E, Ross S, et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review. J Surg Oncol. 2016;113(1):62–83.

    Article  Google Scholar 

  58. Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015;26(7):943–8.

    Article  Google Scholar 

  59. Giorgio A, Calisti G, DE Stefano G, Farella N, DI Sarno A, Amendola F, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single Centre experience. Anticancer Res. 2011;31(12):4575–80.

    PubMed  Google Scholar 

  60. Carrafiello G, Lagana D, Cotta E, Mangini M, Fontana F, Bandiera F, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol. 2010;33(4):835–9.

    Article  Google Scholar 

  61. Zhang SJ, Hu P, Wang N, Shen Q, Sun AX, Kuang M, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2013;20(11):3596–602.

    Article  Google Scholar 

  62. Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011;80(3):e221–5.

    Article  Google Scholar 

  63. Yu MA, Liang P, Yu XL, Cheng ZG, Han ZY, Liu FY, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol. 2011;80(2):548–52.

    Article  Google Scholar 

  64. Schnapauff D, Denecke T, Grieser C, Collettini F, Seehofer D, Sinn M, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2012;35(3):581–7.

    Article  Google Scholar 

  65. Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86.

    Article  Google Scholar 

  66. Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21(4):287–93.

    Article  Google Scholar 

  67. Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr. 2017;6(2):105–16.

    Article  Google Scholar 

  68. Weiner AA, Olsen J, Ma D, Dyk P, DeWees T, Myerson RJ, et al. Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II institutional study. Radiother Oncol. 2016;121(1):79–85.

    Article  Google Scholar 

  69. Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer. 2015;6(11):1099–104.

    Article  Google Scholar 

  70. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34(3):219–26.

    Article  CAS  Google Scholar 

  71. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–8.

    Article  CAS  Google Scholar 

  72. Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10(6):507–20.

    Article  CAS  Google Scholar 

  73. Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2.

    Article  Google Scholar 

  74. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100(11):2426–30.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA

    Nikitha Murali, Lynn Jeanette Savic, Nariman Nezami & Julius Chapiro

  2. Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA

    Lynn Jeanette Savic

  3. Department of Radiology and Biomedical Imaging, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA

    Nariman Nezami & Julius Chapiro

  4. PreScience Labs LLC, Westport, CT, USA

    Jean-François Geschwind

Authors
  1. Nikitha Murali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn Jeanette Savic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nariman Nezami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julius Chapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-François Geschwind
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-François Geschwind .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital Midtown, Atlanta, GA, USA

    Kenneth Cardona

  2. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA

    Shishir K. Maithel

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Murali, N., Savic, L.J., Nezami, N., Chapiro, J., Geschwind, JF. (2018). Regional Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma. In: Cardona, K., Maithel, S. (eds) Primary and Metastatic Liver Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-91977-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91977-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91976-8

  • Online ISBN: 978-3-319-91977-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation